Top-Rated StocksTop-RatedNASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis $10.94 -0.52 (-4.54%) Closing price 04:00 PM EasternExtended Trading$10.93 -0.01 (-0.09%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sutro Biopharma Stock (NASDAQ:STRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sutro Biopharma alerts:Sign Up Key Stats Today's Range$10.59▼$11.4750-Day Range$10.52▼$25.5352-Week Range$7.15▼$43.85Volume363,464 shsAverage Volume302,680 shsMarket Capitalization$181.39 millionP/E RatioN/ADividend YieldN/APrice Target$49.50Consensus RatingBuy Company Overview Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company uses its proprietary cell-free protein synthesis and protein-engineering platforms to design and manufacture complex biologic medicines, including antibody-drug conjugates (ADCs) and immuno-oncology treatments. Sutro’s principal product candidate is luveltamab tazevibulin, also known as luvelta or STRO-002, an ADC designed to target folate receptor alpha, a protein expressed in several cancers. The company has also developed additional investigational programs directed at cancer-related targets and continues to evaluate new therapies generated through its research platforms. Founded in 2003 and headquartered in South San Francisco, California, Sutro conducts research and clinical development activities that support potential treatments for patients in the United States and other international markets. William J. Newell has served as the company’s chief executive officer and has been associated with Sutro since its early development.AI Generated. May Contain Errors. Read More Sutro Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreSTRO MarketRank™: 3.531818181815 of 5 starsSutro Biopharma scored higher than 71% of companies evaluated by MarketBeat, and ranked 178th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSutro Biopharma has a consensus price target of $49.50, representing about 352.5% upside from its current price of $10.94.Amount of Analyst CoverageSutro Biopharma has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sutro Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sutro Biopharma are expected to grow in the coming year, from ($8.41) to ($6.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Sutro Biopharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.35% of the float of Sutro Biopharma has been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 6.47.Change versus previous monthShort interest in Sutro Biopharma has recently decreased by 11.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.59 News SentimentSutro Biopharma has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sutro Biopharma this week, compared to 3 articles on an average week.Search Interest3 people have searched for STRO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders1.80% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sutro Biopharma's insider trading history. Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STRO Stock News HeadlinesSutro Biopharma Announces Participation at the 17th Annual World ADC ConferenceOctober 12, 2026 | markets.businessinsider.comVaxcyte Prices $1 Billion in Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesOctober 6, 2026 | quiverquant.comQFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 16 at 1:00 AM | Weiss Ratings (Ad)Vaxcyte Announces Webcast and Conference Call to Present Topline Data from OPUS-1 Phase 3 Trial of VAX-31 in AdultsOctober 4, 2026 | quiverquant.comQSutro Biopharma, Inc. Announces Appointment of Lucas Donigian as Senior Vice President, Business Development, Effective September 28, 2026September 30, 2026 | marketscreener.comMSutro Biopharma nomina Lucas Donigian come responsabile dello sviluppoSeptember 29, 2026 | it.investing.comSutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business DevelopmentSeptember 29, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)August 14, 2026 | theglobeandmail.comSee More Headlines STRO Stock Analysis - Frequently Asked Questions How have STRO shares performed this year? Sutro Biopharma's stock was trading at $11.57 at the beginning of the year. Since then, STRO stock has decreased by 5.4% and is now trading at $10.94. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) released its quarterly earnings data on Wednesday, August, 12th. The company reported ($2.33) EPS for the quarter, missing the consensus estimate of ($2.19) by $0.14. The business earned $9.84 million during the quarter, compared to analysts' expectations of $11.96 million. When did Sutro Biopharma's stock split? Sutro Biopharma's stock reverse split on the morning of Wednesday, December 3rd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $85 million in an IPO on Thursday, September 27th 2018. The company issued 5,667,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include Iovance Biotherapeutics (IOVA), NVIDIA (NVDA), Rocket Pharmaceuticals (RCKT), Viking Therapeutics (VKTX), IDEAYA Biosciences (IDYA), Krystal Biotech (KRYS) and Nkarta (NKTX). Company Calendar Last Earnings8/12/2026Today10/16/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 3 days ago, STRO's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:STRO CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees128Year Founded2003Price Target and Rating Average Price Target for Sutro Biopharma$49.50 High Price Target$60.00 Low Price Target$34.00 Potential Upside/Downside+352.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($11.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$191.09 million Net Margins-395.25% Pretax Margin-395.46% Return on EquityN/A Return on Assets-88.12% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.32 Sales & Book Value Annual Sales$102.48 million Price / Sales1.77 Cash FlowN/A Price / Cash FlowN/A Book Value($15.43) per share Price / Book-0.71Miscellaneous Outstanding Shares16,580,000Free Float16,283,000Market Cap$181.39 million OptionableOptionable Beta1.49 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:STRO) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThe oil check Munger called his best dealCharlie Munger's $1,000 oil investment in 1962 later paid about $70,000 a year, totaling roughly $1 million ov...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
